VCP Scanner
ScreenerTechnicalBreakoutsThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistPricing
ScreenerTechnical ScannerBreakoutsThemes
Earnings
WatchlistPricing
Ctrl K
INDP
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsCompareWatchlist
INDPIndaptus Therapeutics, Inc.
$1.85$215M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksINDPEarnings History

INDP logoIndaptus Therapeutics, Inc. (INDP) Earnings History

Net Loss

18 years of earnings data (2008–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$15M
● Net Loss
TTM EPS (Diluted)
$-0.13
Per share, diluted
YoY EPS Growth
-1240.4%
Declining
Net Margin
N/A
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating MarginN/A
Gross MarginN/A
Return on Equity-587.6%
Return on Assets-250.5%
Record Annual Net Income-$4MFY2020
Record Quarterly EPS$-0.02Q2 2026
Consecutive Profitable Years0years
Q2 2026
Net Income-$2M
EPS (Diluted)$-0.02
YoY Growth-1240.4%Declining
QoQ Growth+29.4%Excellent

Loading earnings history...

Indaptus Therapeutics, Inc. (INDP) Earnings Overview

As of September 9, 2026, Indaptus Therapeutics, Inc. (INDP) reported trailing twelve-month net income of -$15M, reflecting -1240.4% year-over-year growth. The company earned $-0.13 per diluted share over the past four quarters.

Looking at the long-term picture, INDP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$4M in fiscal 2020.

Indaptus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including IMVT (-$538M net income), KYMR (-$300M net income, -794.4% margin), RCUS (-$452M net income, -142.9% margin), INDP has comparable earnings metrics. Compare INDP vs IMVT →

INDP Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
INDP logoINDPCurrent
-$15M$-0.13--587.6%-1240.4%—
IMVT logoIMVT
-$538M$-2.62--64.8%-1.5%
KYMR logoKYMR
-$300M$-3.05-794.4%-25.8%-23.8%
RCUS logoRCUS
-$452M$-3.58-142.9%-63.3%-4.8%
TGTX logoTGTX
$441M$2.8172.6%102.8%+1746.7%
NKTX logoNKTX
-$117M$-1.57--28.9%+11.9%
Best in group
Lowest in group

INDP Historical Earnings Data (2008–2025)

18 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$21M-38.8%-$20M$-21.58--
2024-$15M+2.6%-$15M$-1.61--
2023-$15M-7.7%-$16M$-1.84--
2022-$14M-85.7%-$15M$-1.73--
2021-$8M-115.2%-$8M$-1.89--
2020-$4M+92.5%-$4M$-0.66--
2019-$48M-9.3%-$35M$-112.74--
2018-$44M-50.6%-$43M$-111.67--
2017-$29M-116.4%-$29M$-130.96--
2016-$13M-86.2%-$14M$-93.38--
2015-$7M-26.0%-$8M$-73.70--
2014-$6M-11.8%-$8M$-1.89--
2013-$5M+1.7%-$5M$-1.90--
2012-$5M+31.6%-$5M$-2.14--
2011-$8M-39.8%-$8M$-3.55--
2010-$5M-37.6%-$5M$-3.17--
2009-$4M+26.5%-$4M$-3.54--
2008-$5M--$5M$-7.48--

Download Data

Export INDP earnings history in CSV or JSON format

Free sign-in required to download data

Consensus & Technical Research Suite
Open INDP Terminal

INDP Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

18+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

INDP — Frequently Asked Questions

Quick answers to the most common questions about buying INDP stock.

What is INDP earnings per share (EPS)?

INDP trailing twelve-month (TTM) diluted EPS is $-0.13, reflecting -1240.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2008 to 2025 is available in the table on this page.

What is Indaptus Therapeutics, Inc.'s net income?

Indaptus Therapeutics, Inc. (INDP) trailing twelve-month net income is $-15M as of 2025. Earnings declined -1240.4% year-over-year.

Is INDP profitable?

INDP is not currently profitable on a TTM basis, reporting a net loss of $-15M. Net margin is N/A. Investors should monitor for a return to profitability.

What is INDP's earnings growth rate?

INDP compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2008 to 2025.

What are INDP's profit margins?

Indaptus Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -587.6%.

Is INDP growing earnings?

INDP earnings are declining — EPS fell -1240.4% year-over-year. TTM net income dropped to $-15M. This contrasts with the 5-year CAGR of N/A.

What was INDP's best earnings year?

Indaptus Therapeutics, Inc.'s highest annual net income on record is $-4M, achieved in fiscal year 2020. Earnings history on this page spans 2008 to 2025 and includes all annual and quarterly figures.

What were INDP's earnings last quarter?

INDP's most recent reported quarter was Q2 2026. Net income was $-2M with diluted EPS of $-0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.

INDP Earnings Over Time (2008–2025)

Net income & EPS — annual and quarterly view